Postoperative Adjuvant Combination Therapy with Doxorubicin and Noncytotoxic Suramin in Dogs with Appendicular Osteosarcoma

Abstract

Although conventional treatment of dogs with osteosarcoma (OSA) by amputation and chemotherapy results in reported survival times (STs) of 262-413 days, no major improvements in STs have occurred in the past 2 decades. Suramin is a polysulfonated napthylurea, which at noncytotoxic concentrations in vitro, increases tumor sensitivity to chemotherapy, including doxorubicin. The study authors evaluated the combination of noncytotoxic suramin and doxorubicin after amputation in dogs with OSA. The hypothesis was that treatment of dogs with appendicular OSA with amputation, adjuvant doxorubicin, and noncytotoxic suramin would be well tolerated and result in STs at least comparable to those of doxorubicin alone. Forty-seven dogs received 6.75 mg/kg of suramin IV followed by 30 mg/m(2) of doxorubicin IV 4 hr later. Treatment was repeated q 2 wk for five doses. The median disease free time (DFI) was 203 days (range, 42-1,580+ days) and the median ST for all dogs was 369 days (range, 92-1,616+ days). There was no statistical difference in ST and DFI between greyhounds and nonngreyhounds. Adjuvant doxorubicin and noncytotoxic suramin was well tolerated in dogs with OSA following amputation. Additional studies are needed to determine if this combination treatment protocol provides additional clinical benefit compared with doxorubicin alone.

What do we know about canine osteosarcoma treatment? – review

“…Authors evaluated the combination of noncytotoxic suramin and doxorubicin after amputation in dogs with OSA. In conclusion of this experiment similar results to monotherapy median disease free time was achieved (Alvarez et al 2014 ). Also Kurzman and associates ( 1995 ) showed that benefits of adding Liposome-encapsulated Muramyl Tripeptyde to standard chemotherapy treatment (with cisplatin) and surgery is time.…”

Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics

“…However there is evidence suggesting six doses of carboplatin may be superior to alternating doxorubicin and carboplatin regimens [ 53 ]. In canine OSA adjuvant chemotherapy with either doxorubicin or the platinum-based compounds including cisplatin and carboplatin have been associated with increased survival times over amputation alone [ 54 – 57 ]. The relative merits of the individual chemotherapy drugs have been evaluated.…”

Triptolide induces the cell apoptosis of osteosarcoma cells through the TRAIL pathway

“…Characterized by high malignant potential and invasive ability, osteosarcoma, a common tumor in adolescents, exhibits lung metastasis at an early stage (19). Consequently, it is associated with a poor prognosis and a low survival rate.…”